The protein products of these genes include targets for treatments to stimulate (thyrotropin [TSH]) or suppress (methimazole, targeting thyroid peroxidase, TPO) thyroid function, and drugs to treat thyroid cancer (e.g. the KDR inhibitor, vandetanib) as well as PDE4 inhibitors and AKT inhibitors utilised in immunoinflammatory conditions and cancers (Supplementary Data 8). Here, AKT1 is linked to thyroid gland carcinoma.